MHRA withdraws IXCHIQ after safety review tips benefit-risk balance against the vaccine
The UK has pulled IXCHIQ, the live attenuated chikungunya vaccine, from the market after the Medicines and Healthcare products Regulatory Agency concluded that its benefit-risk balance is no longer favourable. The decision follows advice from the Commission on Human Medicines and applies immediately: healthcare professionals should no longer prescribe, supply, or administer the vaccine in the UK.
The regulatory action is unusually firm for a travel vaccine, but the clinical logic is straightforward. A product intended to prevent infection in travellers must offer a safety profile that remains acceptable when deployed in generally healthy people who may already be managing chronic disease, older age, or multiple medications. Once serious adverse reactions began to accumulate after authorisation, the balance changed.
Serious adverse reactions shifted the calculus
IXCHIQ was authorised for adults travelling to high-risk areas where chikungunya transmission occurs. Since authorisation, serious adverse reactions have been reported, including chikungunya-like symptoms and rare neurological events such as encephalitis. Cases were seen predominantly in older adults and people with underlying medical conditions, but reactions were also reported in individuals with no known health problems.
Some of those reports resulted in hospitalisation or death.
That safety pattern is clinically important because a live attenuated vaccine is designed to stimulate immune protection through limited viral replication. In most recipients that approach is tolerated, but in susceptible patients it can create a narrower margin between expected reactogenicity and true harm. Neurological complications, even if rare, carry disproportionate weight in a preventive product aimed at travellers, where the alternative risk-reduction toolkit includes non-pharmacological measures and, in some settings, other vaccines.
The MHRA’s conclusion rests on a post-authorisation review of safety data and consultation with the CHM. The agency determined that the benefits of receiving IXCHIQ for UK travellers no longer outweigh the risks. For a vaccination programme built around prevention rather than treatment, that is the decisive regulatory threshold.
What clinicians should do now
Healthcare professionals are being told not to prescribe, supply, or administer IXCHIQ and to dispose of any remaining stock according to local policy. Materials, systems, and patient-facing communications that list available UK vaccination options also need to be updated so the vaccine is removed from clinical workflows and travel advice resources.
The guidance leaves no ambiguity at the bedside. Travellers who previously received IXCHIQ do not need revaccination or any specific medical treatment because of this decision. There is also no risk to people who were vaccinated and did not develop side effects. Patients who experienced a suspected adverse reaction after vaccination should seek medical advice and report the event through the Yellow Card scheme.
For current travellers, prevention shifts back to the measures that have always sat beside vaccination: avoidance of mosquito bites, use of repellent and netting, and adherence to current health-related travel advice. Where an alternative chikungunya vaccine is available, that option should be considered within the context of local recommendations and individual risk.
Why older adults and medically complex patients mattered most
The background safety signal concentrated in older adults and in people with underlying conditions, two groups that are common in travel medicine clinics. Those are the very patients in whom clinicians often seek a simple preventive intervention before departure, especially when a destination has established arboviral transmission and mosquito exposure may be prolonged.
For those patients, a vaccine-related adverse event can create a cascade: emergency assessment, imaging, infectious or neurological workup, hospital admission, and uncertainty over whether symptoms reflect vaccine reaction, coincident infection, or another acute process. A product with even a small chance of severe neurological toxicity becomes difficult to justify when the target population includes travellers whose baseline risk may be reduced through bite prevention and itinerary advice.
The case also illustrates a broader feature of post-marketing pharmacovigilance. Pre-authorisation studies are rarely large enough to detect uncommon but serious harms with confidence, particularly when those harms emerge in older or medically complex subgroups. Once a vaccine moves into real-world use, rare events can surface quickly enough to change regulatory judgement, especially when the adverse event is severe and the indication is preventive rather than therapeutic.
Yellow Card reporting remains central after withdrawal
The MHRA is still asking healthcare professionals, patients, and caregivers to report suspected adverse reactions through the Yellow Card scheme. Reports can be submitted on the Yellow Card website, through the app, or via compatible clinical IT systems including EMIS, SystmOne, Vision, MiDatabank, and Ulysses.
Complete reporting matters here because the agency is still building the real-world safety picture around the product’s post-licensing experience. When clinicians submit reports, they are asked to include medical history, concomitant medication, the timing of symptom onset, and treatment dates. Those details help pharmacovigilance teams separate vaccine-associated events from background illness and identify patterns that may not be visible in smaller datasets.
For now, the practical instruction is uncompromising: IXCHIQ is no longer a UK vaccination option. The remaining clinical task is to protect travellers through other preventive strategies and to document any suspected harm with enough detail to support ongoing safety surveillance.